Acute lymphocytic leukemia (Ph-positive) is a dubious disease in the field of blood tumours, clinical performance is complex and often involves multi-systematic strain. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in matching a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment. Treatment and management of acute lymphocytic leukemia Ph-positive treatments require individual development, usually including multidimensional management, including drug therapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many blood tumor diseases that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner depending on the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of acute lymphocytic leukemia Ph-positive. The platform serves a team of domestic and foreign experts in the field of blood tumours in the Chinese international medical service system, providing the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.